Hostname: page-component-84b7d79bbc-x5cpj Total loading time: 0 Render date: 2024-07-30T12:08:06.789Z Has data issue: false hasContentIssue false
  • English
  • Français

Effects of atypical and typical antipsychotic treatments on sexual function in patients with schizophrenia: 12-month results from the Intercontinental Schizophrenia Outpatient Health Outcomes (IC-SOHO) study

Published online by Cambridge University Press:  16 April 2020

Martin Dossenbach ,
Yulia Dyachkova ,
Sebnem Pirildar ,
Martin Anders ,
Afaf Khalil ,
Aleksander Araszkiewicz ,
Tamara Shakhnovich ,
Aly Akram ,
Jan Pecenak  and
Margaret McBride
...Show all authors
Martin Dossenbach*
Affiliation:
Eli Lilly and Company, Ges.m.b.H, Köclblgasse 8-10, 1030Vienna, Austria
Yulia Dyachkova
Affiliation:
Eli Lilly and Company, Ges.m.b.H, Köclblgasse 8-10, 1030Vienna, Austria
Sebnem Pirildar
Affiliation:
Ege University, Medical Faculty, Department of Psychiatry, Izmir, Turkey
Martin Anders
Affiliation:
Department of Psychiatry 1st Medical Faculty, Charles University, Ke Karlovu 11, 120 00Prague 2, Czech Republic
Afaf Khalil
Affiliation:
Ein Shames University Hospital, Department of Psychiatry, Heliopolis, Cairo, Egypt
Aleksander Araszkiewicz
Affiliation:
Department of Psychiatry, Bydgoszcz University Medical School, Poland
Tamara Shakhnovich
Affiliation:
Psychiatry Hospital N4, 3 Poteshnaya Str., 123298, Moscow, Russia
Aly Akram
Affiliation:
Suliman Faqueeh Hospital, Jeddah, Saudi Arabia
Jan Pecenak
Affiliation:
Department of Psychiatry, Faculty of Medicine, Comenius University, University Hospital Bratislava, Mickiewiczova 13, 81369Bratislava, Slovakia
Margaret McBride
Affiliation:
Eli Lilly and Company, Sydney, Australia
Tamas Treuer
Affiliation:
Eli Lilly and Company, Ges.m.b.H, Köclblgasse 8-10, 1030Vienna, Austria
*
*Corresponding author. Tel.: +43 1711 78 624; fax: +43 1711 78551. E-mail address: d.m@lilly.com (M. Dossenbach).
Get access

Abstract

Purpose

Sexual dysfunction in patients with schizophrenia can reduce quality of life and treatment compliance. This report will compare the effects of selected atypical and typical antipsychotics on sexual function in a large, international population of outpatients with schizophrenia who were treated over 1 year.

Subjects and methods

Outpatients with schizophrenia, who initiated or changed antipsychotic treatment, and entered this 3-year, prospective, observational study were classified according to the monotherapy prescribed at baseline: olanzapine (N = 2638), risperidone (N = 860), quetiapine (N = 142) or haloperidol (N = 188).

Results

Based on patient perception, the odds of experiencing sexual dysfunction during 1 year of therapy was significantly lower for patients treated with olanzapine and quetiapine when compared to patients who received risperidone or haloperidol (all P ≤ 0.001). Females on olanzapine (14%) or quetiapine (8%) experienced a lower rate of menstrual irregularities, compared to females on risperidone (23%) or haloperidol (29%). Significant discordance was evident between patient reports and psychiatrist perception of sexual dysfunction, with psychiatrists underestimating sexual dysfunction (P ≤ 0.001).

Conclusions

These findings indicate clinically relevant differences exist in the sexual side effect profiles of these selected antipsychotics. These factors should be considered when selecting the most appropriate treatment for outpatients with schizophrenia.

Keywords

SchizophreniaSexual dysfunctionHyperprolactinemiaAntipsychotic agents
Type
Original articles
Information
European Psychiatry , Volume 21 , Issue 4 , June 2006 , pp. 251 - 258
Copyright
Copyright © European Psychiatric Association 2006

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

Aizenberg, D, Zemishlany, Z, Dorfman-Etrog, P, Weizman, ASexual dysfunction in male schizophrenic patients. J. Clin. Psychiatry 1995;56:137–141.Google ScholarPubMed
American Psychiatric Association Diagnostic and Statistical Manual of Mental Disorders. 4th edWashington, DC: APA; 1994.Google Scholar
Arvanitis, LA, Miller, BGSeroquel Trial 13 Study Group. Multiple fixed doses of “Seroquel” (quetiapine) in patients with acute exacerbation of schizophrenia: a comparison with haloperidol and placebo. Biol. Psychiatry 1997;42:233–246.CrossRefGoogle Scholar
Bobes, J, Garcia-Portilla, MP, Rejas, J, Hernandez, G, Garcia-Garcia, M, Rico-Villademoros, Fet al.Frequency of sexual dysfunction and other reproductive side-effects in patients with schizophrenia treated with risperidone, olanzapine, quetiapine, or haloperidol: the results of the EIRE study. J. Sex Marital Ther. 2003;29:125–147.CrossRefGoogle ScholarPubMed
Compton, MT, Miller, AHSexual side effects associated with conventional and atypical antipsychotics. Psychopharmacol. Bull. 2001;35:89–108.Google ScholarPubMed
Cutler, AJSexual dysfunction and antipsychotic treatment. Psychoneuroendocrinology 2003;28:69–82.CrossRefGoogle ScholarPubMed
David, S, Taylor, C, Kinon, B, Breier, AThe effects of olanzapine, risperidone and haloperidol on plasma prolactin levels in patients with schizophrenia. Clin. Ther. 2000;22:1085–1096.CrossRefGoogle ScholarPubMed
Dickson, RA, Glazer, WMNeuroleptic-induced hyperprolactinemia. Schizophr. Res. 1999;35(Suppl):75–86.CrossRefGoogle ScholarPubMed
Dickson, RA, Seeman, MV, Corenblum, BHormonal side effects in women: typical versus atypical antipsychotic treatment. J. Clin. Psychiatry 2000;13(Suppl):23–30.Google Scholar
Dossenbach, M, Erol, A, el Mahfoud Kessaci, M, Shahen, MO, Sunbol, MM, Boland, Jet al.Effectiveness of antipsychotic treatments for schizophrenia—analysis from a prospective observational study (IC-SOHO) comparing olanzapine, quetiapine, risperidone and haloperidol. J. Clin. Psychiatry 2004;65:312–321.CrossRefGoogle Scholar
Dossenbach, M, Hodge, A, Anders, M, Molnár, B, Peciukaitiene, D, Krupka-Matuszczyk, Iet al.Prevalence of sexual dysfunction in patients with schizophrenia: international variation and underestimation. Int. J. Neuropsychopharmacol. 2005;8:195–201.CrossRefGoogle ScholarPubMed
Fleischhacker, WW, Meise, U, Gunther, V, Kurz, MCompliance with antipsychotic drug treatment: influence of side effects. Acta Psychiatr. Scand. 1994;382(Suppl):11–15.Google ScholarPubMed
Friedman, S, Harrison, GSexual histories, attitudes, and behaviour of schizophrenic and “normal” women. Arch. Sex. Behav. 1984;13:555–567.CrossRefGoogle ScholarPubMed
Ghadirian, AM, Chouinard, G, Annable, LSexual dysfunction and plasma prolactin levels in neuroleptic-treated schizophrenic outpatients. J. Nerv. Ment. Dis. 1982;170:463–467.CrossRefGoogle ScholarPubMed
Halbreich, U, Kinon, BJ, Gilmore, JA, Kahn, LSElevated prolactin levels in patients with schizophrenia: mechanisms and related adverse effects. Psychoneuroendocrinology 2003;28(Suppl):53–67.CrossRefGoogle ScholarPubMed
Kim, KS, Pae, CU, Chae, JH, Bahk, WM, Jun, TY, Kim, DJet al.Effects of olanzapine on prolactin levels of female patients with schizophrenia treated with risperidone. J. Clin. Psychiatry 2003;63:408–413.CrossRefGoogle Scholar
Kinon, BJ, Gilmore, JA, Liu, H, Halbreich, UMPrevalence of hyperprolactinemia in schizophrenic patients treated with conventional antipsychotic medications or risperidone. Psychoneuroendocrinology 2003;28:55–68.CrossRefGoogle ScholarPubMed
Kleinberg, DL, Davis, JM, de Coster, R, Van Baelen, B, Brecher, MProlactin levels and adverse events in patients treated with risperidone. J. Clin. Psychopharmacol. 1999;19:57–61.CrossRefGoogle ScholarPubMed
Knegtering, H, Blijd, C, Boks, M.P.M.Sexual dysfunctions and prolactin levels in patients using classical antipsychotics, risperidone or olanzapine. Schizophr. Res. 1999;36:355–356.Google Scholar
Knegtering, H, van der Moolen, AE, Castelein, S, Kluiter, H, van den Bosch, RJWhat are the effects of antipsychotics on sexual dysfunctions and endocrine functioning?. Psychoneuroendocrinology 2003;28:109–123.CrossRefGoogle ScholarPubMed
Lingjaerde, O, Ahlfors, UG, Bech, P, Dencker, SJ, Elgen, KThe UKU Side Effect Rating Scale: a new comprehensive rating scale for psychotropic drugs, and a cross-sectional study of side effects in neuroleptic-treated patients. Acta Psychiatr. Scand. 1987;(Suppl. 76):1–100.CrossRefGoogle Scholar
Maguire, GAProlactin elevation with antipsychotic medications: mechanisms of action and clinical consequences. J. Clin. Psychiatry 2002;63(Suppl 4):56–62.Google ScholarPubMed
Meany, AM, O’Keane, VProlactin and schizophrenia: clinical consequences of hyperprolactinaemia. Life Sci. 2002;71:979–992.CrossRefGoogle Scholar
Perkins, DOPredictors of noncompliance in patients with schizophrenia. J. Clin. Psychiatry 2002;63:1121–1128.CrossRefGoogle ScholarPubMed
Peuskens, J, Sienaert, P, De Hert, MSexual dysfunction: the unspoken side effect of antipsychotics. Eur. Psychiatry 1998;13(Suppl 1):23–30.CrossRefGoogle ScholarPubMed
Raja, M, Azzoni, ASexual behavior and sexual problems among patients with severe chronic psychoses. Eur. Psychiatry 2003;18:70–76.CrossRefGoogle ScholarPubMed
Sacristan, JA, Gomez, JC, Montejo, AL, Vieta, E, Gregor, KJDoses of olanzapine, risperidone and haloperidol used in clinical practice: results of a prospective pharmacoepidemiologic study. EFESO Study Group. Estudio Farmacoepidemiologico en la Esquizofrenia con Olanzapina. Clin. Ther. 2000;22:583–599.CrossRefGoogle Scholar
Tran, PV, Hamilton, SH, Kuntz, AJ, Potvin, JH, Andersen, SW, Beasley, Cet al.Double-blind comparison of olanzapine versus risperidone in the treatment of schizophrenia and other psychotic disorders. J. Clin. Psychopharmacol. 1997;17:407–418.CrossRefGoogle ScholarPubMed
Volavka, J, Czobor, P, Cooper, TB, Sheitman, B, Lindenmayer, JP, Citrome, Let al.Prolactin levels in schizophrenia and schizoaffective disorder patients treated with clozapine, olanzapine, risperidone, or haloperidol. J. Clin. Psychiatry 2004;65:57–61.CrossRefGoogle ScholarPubMed
World Health Organization The ICD-10 Classification of mental and behavioural disorders: clinical descriptions and diagnostic guidelines. Geneva: WHO; 1992.Google Scholar
Submit a response

Comments

No Comments have been published for this article.